Crystal S. Denlinger, MD

Request an Appointment Online - Click Here New patients can request an appointment online or call

Fox Chase Cancer Center
333 Cottman Ave
Philadelphia, PA 19111-2497

Colorectal Cancer Treatment at Fox Chase Cancer Center

GI Service Line

Learn about colorectal cancer treatment at Fox Chase Cancer Center. From diagnosis to treatment to concerns about your family, our team has experience than can help. (9 min.)

Patient Stories from Fox Chase Patients Dr. Denlinger's
Patient Stories

  • Gary Burk - Pancreatic Cancer Patient Stories
  • Janice GaNun - Clinical-Trials Patient Stories, Pancreatic Cancer Patient Stories
  • Carol Hobson - Liver Cancer (Bile Duct Cancer) Patient Stories
  • Barbara Lanza - Pancreatic Cancer Patient Stories
NCCN Presents New Guidelines for Survivorship
(Mar 15, 2013)
Key to proper survivorship care, noted Dr. Denlinger, Chair of the Guidelines Panel, is accurate assessment of survivor’s needs and concerns on a routine basis.
Fox Chase Clinical Trial Tests First of Its Kind Antibody: MM-111 Antibody Uses HER2 Target to Reach and Block HER3
(Jun 7, 2010)

Dr. Denlinger talks about chemotherapy side effects, WHYY FM, 1/27/2009

Dr. Crystal Denlinger


Assistant Professor 
Co-Site Director, Temple University 
Internal Medicine Residency and Student Program at Fox Chase

Meet other members of the
gastrointestinal cancer treatment team

Clinical Expertise:

Colorectal Cancer; Pancreatic Cancer; Gastrointestinal Cancers; Esophagus and Stomach Cancer and Liver cancer


American Board of Internal Medicine;
Medical Oncology

Medical Education

New Jersey Medical School, University of Medicine & Dentistry of New Jersey, Newark, N.J., 2001


Internal Medicine, Mount Sinai Medical Center, New York, N.Y.


Hematology-Oncology, Fox Chase Cancer Center and Temple University Hospital, Phila., Pa., Chief Fellow

Research Interests

Gastrointestinal cancers; Cancer Survivorship; Drug Development


Dr. Denlinger on My NCBI 

  1. Denlinger CS, Blanchard R, Xu L, Bernaards C, Litwin S, Spittle C, Berg DJ, McLaughlin S, Redlinger M, Dorr A, Hambleton J, Holden S, Kearns A, Kenkare-Mitra S, Lum B, Meropol NJ, O’Dwyer PJ.  Pharmacokinetic and pharmacogenetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.  Cancer Chemotherapy and Pharmocology, Dec;65(1):97-105, 2009. Epub 2009 May 5. PMID: 2746259,NIHMS 110194. Pub Med
  2. Denlinger CS, Barsevick AM.  The challenges of colorectal cancer survivorship.  Journal of the National Comprehensive Cancer Network, 7(8):  883-894, 2009.  PMID: 19755048. Pub Med
  3. Denlinger CS, Engstrom PF. Colorectal cancer survivorship: movement matters. Cancer Prevention Research, 4(4):502-11, Apr, 2011.  Epub April 3, 2011.  PMID: 21464030. Pub Med
  4. Dotan E, Browner I, Hurria A, Denlinger C. Challenges in the Management of Older Patients With Colon Cancer. Journal of the National Comprehensive Cancer Network,  10(2): p. 213-224, 2012. PMID:  22308516. Pub Med
  5. Ligibel JA and Denlinger CS.  New NCCN Guidelines(R) for survivorship care.  Journal of the National Comprehensive Cancer Network, 11(5 Suppl):  640-644, 2013. Pub Med
  6. Denlinger CS, Meropol NJ, Li T, Lewis NL, Engstrom PF, Weiner LM, Cheng JD, Alpaugh RK, Cooper H, Wright JJ, Cohen SJ.  A phase II trial of bortezomib in patients with advanced biliary tract cancers.  Clinical Colorectal Cancer 13(2):  81-86, 2014  .Epub ahead of print Jan 4 2014.  PMID 24512954. Pub Med
  7. Denlinger CS and Ligibel J.  A Work In Progress:  Developing the new NCCN Survivorship Guidelines.  Journal of the National Comprehensive Cancer Network, 12(1):  1-4, 2014.  PMID:  24453287. Pub Med
  8. Dotan E, Devarajan K, D’Silva AJ, Beck A, Kloth DD, Cohen SJ, Denlinger C.  Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies in older adults with metastatic colorectal cancer.  Clinical Colorectal Cancer 2014 Sept; 13(3):  192-198. Epub ahead of print Jun 26 2014.  PMID:  25074246. Pub Med
  9. Morgan MA, Denlinger CS.  Survivorship: tools for transitioning patients with cancer. Journal of the National Comprehensive Cancer Network. 2014 Dec;12(12):1681-1687.  PMID:25505209.   Pub Med
  10. Shah M and Denlinger CS.  Optimal post-treatment surveillance in cancer survivors:  is more really better?  Oncology 2015 29(4):  230-240. PMID: 25952485. Pub Med
  11. Vijayvergia N and Denlinger CS. Lifestyle factors in Cancer Survivorship: Where we are and where we are headed.  Journal of Personalized Medicine. 2015 5(3): 243-263. Pub Med
  12. Vijayvergia N, Shah PC, Denlinger CS.  Survivorship in non-small cell lung cancer:  challenges faced and steps forward.  Journal of the National Comprehensive Cancer Network.  2015 Sep;13(9):1151-61. PMID: 26358799. Pub Med